Q-omics provides the consensus-scored NUTM2G profile across patient tissues and cancer cell-line models. NUTM2G expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NUTM2G is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, NUTM2G RNA expression shows 17,867 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where NUTM2G shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUTM2G — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUTM2G survival associations across molecular data types. NUTM2G RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUTM2G RNA expression–survival associations across cancer types. High NUTM2G expression shows unfavorable associations in ACC, COAD, LGG and BLCA, but favorable associations in THYM and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NUTM2G RNA expression.
This table summarizes NUTM2G tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for NUTM2G. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUTM2G shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, CHOL, COAD and READ. The HNSC box plot shows higher NUTM2G RNA expression in tumor versus normal tissue (log2 FC = +0.175, t-test p < 0.001).
This table shows molecular features associated with NUTM2G in patient tissues and cancer cell lines. In patient samples, NUTM2G shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NUTM2G RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
